With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences. Review: ...

Why a Malvern biopharma is exploring combining its lead drug candidate targeting Alzheimer's and Parkinson's diseases with a ...

The 2024 Trends Shaping the Health Economy report gave a past, present, and future look at diabetes care in the US and the ...

Many people who take GLP-1 drugs find that their cravings disappear. I went to a Buddhist monastery to try to understand why ...

Should you, would you, take Ozempic? It's a question I'm asked by friends and it's a hot topic among my scientist colleagues, ...

A series of state and federal lawsuits challenging coverage exclusions for obesity drugs and procedures are testing the ...

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...